UW Directories | Calendar | Map | MyUW
UW logo
Skip to Main
Human Subjects Division (HSD)

Regulatory Updates

FDA Issues Draft Guidance on Risk-Based Approaches for Monitoring Clinical Investigations

Aug 30, 2011 at 6:57am

FDA has issued draft guidance on "Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring." The guidance document is now available from the FDA's web site using the following web link:

 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdfguidance

The new draft guidance is being issued to assist sponsors of clinical investigations in developing risk-based monitoring strategies and plans for clinical investigations of human drug and biological products, medical devices, and combinations thereof.  This guidance is intended to make clear that sponsors can use a variety of approaches to meet their monitoring responsibilities during clinical investiations. This guidance describes a modern, risk-based approach to monitoring that focuses on critical study parameters and relies on a combination of monitoring activities to effectively oversee a study.

Comments to this draft guidance are due by November 28, 2011.